NSG 552 ADVANCED PSYCHOPHARMACOLOGY
MASTER STUDY GUIDE ACTUAL EXAM
QUESTIONS & DETAILED CLINICAL
RATIONALES
Master your advanced psychiatric prescribing boards with this
comprehensive bank of verified multiple-choice questions detailing high-
yield neurobiology, pharmacokinetics, and clinical drug-drug interactions.
Each board-style question is paired with a clear italicized answer and an
exhaustive, bolded rationale designed to simplify complex mechanism-of-
action concepts for Exams 1, 2, and 3. This academic study guide
guarantees an efficient review and a passing grade by matching the
modern Wilkes University advanced psychopharmacology curriculum.
Section 1: Neurobiology, Pharmacokinetics, &
Foundations (Questions 1–15)
Q1: Pharmacokinetics & Enzyme Inhibition
A 42-year-old female stabilized on a maintenance
dose of a narrow therapeutic index medication
metabolized by CYP2D6 is prescribed fluoxetine for
a new-onset major depressive episode. Which of the
following pharmacokinetic mechanisms is most likely
to precipitate clinical toxicity of the primary
medication?
A) Induction of hepatic glucuronidation enzymes
in zone 3 of the liver acinus
B) Competitive and non-competitive inhibition of
hepatic CYP2D6 by fluoxetine and norfluoxetine
, C) Displacement of the co-administered drug
from plasma albumin binding sites
D) Upregulation of renal P-glycoprotein efflux
pumps at the proximal convoluted tubule
Answer: B) Competitive and non-competitive
inhibition of hepatic CYP2D6 by fluoxetine and
norfluoxetine
Rationale: Fluoxetine and its active long-lived
metabolite, norfluoxetine, are potent inhibitors of
the Cytochrome P450 2D6 isoenzyme. Co-
administering fluoxetine with any substrate that
relies heavily on CYP2D6 for clearance (such as
certain beta-blockers, TCAs, or antipsychotics)
leads to a profound drop in metabolic clearance,
causing plasma level accumulation and severe
toxicity risk.
Q2: Receptor Dynamics & Dissociation Constant
A psychiatric-mental health nurse practitioner is
evaluating a novel antipsychotic agent with a very
low dissociation constant (Kdcap K sub d𝐾𝑑) for the
dopamine D₂ receptor. How does this specific Kdcap
K sub d 𝐾𝑑 value translate into the clinical
pharmacodynamic profile of the drug?
, A) Low clinical potency requiring substantially
higher milligram dosing ranges
B) Rapid dissociation kinetics resulting in an
absence of extrapyramidal symptoms
C) High binding affinity requiring a lower
milligram dosage to achieve therapeutic receptor
occupancy
D) High intrinsic activity translating into a full
agonist response profile
Answer: C) High binding affinity requiring a lower
milligram dosage to achieve therapeutic receptor
occupancy
Rationale: The dissociation constant (Kdcap K
sub d 𝐾𝑑) is inversely proportional to a drug's
receptor affinity. A very low Kdcap K sub d
𝐾𝑑 means that the drug binds to the target
receptor with high affinity, requiring a lower
molecular concentration (and lower clinical
milligram dose) to saturate 50% of the receptor
population. It does not dictate intrinsic efficacy
or off-rate kinetics directly.
Q3: Neurotransmitters & Signal Transduction
, During a cellular signal transduction cascade, a G-
protein coupled receptor (GPCR) activates adenylyl
cyclase, which subsequently converts ATP to cyclic
adenosine monophosphate (cAMP). In this
molecular pathway, how is cAMP classified?
A) First messenger
B) Second messenger
C) Third messenger
D) Transcription factor
Answer: B) Second messenger
Rationale: In psychopharmacology and cellular
biology, the neurotransmitter itself acts as the
first messenger. The intracellular molecule
generated downstream of receptor activation—
such as cAMP, inositol triphosphate (IP₃), or
diacylglycerol (DAG)—is classified as the
second messenger, which propagates the signal
inside the neuron.
Q4: Steady-State Pharmacokinetics
A patient is initiated on a new antidepressant with a
plasma elimination half-life of exactly 24 hours.
Assuming linear kinetics and regular daily dosing
without a loading dose, how many days will it take
MASTER STUDY GUIDE ACTUAL EXAM
QUESTIONS & DETAILED CLINICAL
RATIONALES
Master your advanced psychiatric prescribing boards with this
comprehensive bank of verified multiple-choice questions detailing high-
yield neurobiology, pharmacokinetics, and clinical drug-drug interactions.
Each board-style question is paired with a clear italicized answer and an
exhaustive, bolded rationale designed to simplify complex mechanism-of-
action concepts for Exams 1, 2, and 3. This academic study guide
guarantees an efficient review and a passing grade by matching the
modern Wilkes University advanced psychopharmacology curriculum.
Section 1: Neurobiology, Pharmacokinetics, &
Foundations (Questions 1–15)
Q1: Pharmacokinetics & Enzyme Inhibition
A 42-year-old female stabilized on a maintenance
dose of a narrow therapeutic index medication
metabolized by CYP2D6 is prescribed fluoxetine for
a new-onset major depressive episode. Which of the
following pharmacokinetic mechanisms is most likely
to precipitate clinical toxicity of the primary
medication?
A) Induction of hepatic glucuronidation enzymes
in zone 3 of the liver acinus
B) Competitive and non-competitive inhibition of
hepatic CYP2D6 by fluoxetine and norfluoxetine
, C) Displacement of the co-administered drug
from plasma albumin binding sites
D) Upregulation of renal P-glycoprotein efflux
pumps at the proximal convoluted tubule
Answer: B) Competitive and non-competitive
inhibition of hepatic CYP2D6 by fluoxetine and
norfluoxetine
Rationale: Fluoxetine and its active long-lived
metabolite, norfluoxetine, are potent inhibitors of
the Cytochrome P450 2D6 isoenzyme. Co-
administering fluoxetine with any substrate that
relies heavily on CYP2D6 for clearance (such as
certain beta-blockers, TCAs, or antipsychotics)
leads to a profound drop in metabolic clearance,
causing plasma level accumulation and severe
toxicity risk.
Q2: Receptor Dynamics & Dissociation Constant
A psychiatric-mental health nurse practitioner is
evaluating a novel antipsychotic agent with a very
low dissociation constant (Kdcap K sub d𝐾𝑑) for the
dopamine D₂ receptor. How does this specific Kdcap
K sub d 𝐾𝑑 value translate into the clinical
pharmacodynamic profile of the drug?
, A) Low clinical potency requiring substantially
higher milligram dosing ranges
B) Rapid dissociation kinetics resulting in an
absence of extrapyramidal symptoms
C) High binding affinity requiring a lower
milligram dosage to achieve therapeutic receptor
occupancy
D) High intrinsic activity translating into a full
agonist response profile
Answer: C) High binding affinity requiring a lower
milligram dosage to achieve therapeutic receptor
occupancy
Rationale: The dissociation constant (Kdcap K
sub d 𝐾𝑑) is inversely proportional to a drug's
receptor affinity. A very low Kdcap K sub d
𝐾𝑑 means that the drug binds to the target
receptor with high affinity, requiring a lower
molecular concentration (and lower clinical
milligram dose) to saturate 50% of the receptor
population. It does not dictate intrinsic efficacy
or off-rate kinetics directly.
Q3: Neurotransmitters & Signal Transduction
, During a cellular signal transduction cascade, a G-
protein coupled receptor (GPCR) activates adenylyl
cyclase, which subsequently converts ATP to cyclic
adenosine monophosphate (cAMP). In this
molecular pathway, how is cAMP classified?
A) First messenger
B) Second messenger
C) Third messenger
D) Transcription factor
Answer: B) Second messenger
Rationale: In psychopharmacology and cellular
biology, the neurotransmitter itself acts as the
first messenger. The intracellular molecule
generated downstream of receptor activation—
such as cAMP, inositol triphosphate (IP₃), or
diacylglycerol (DAG)—is classified as the
second messenger, which propagates the signal
inside the neuron.
Q4: Steady-State Pharmacokinetics
A patient is initiated on a new antidepressant with a
plasma elimination half-life of exactly 24 hours.
Assuming linear kinetics and regular daily dosing
without a loading dose, how many days will it take
